No connection

Search Results

AYTU vs TELA

AYTU
Aytu BioPharma, Inc.
NEUTRAL
Price
$2.70
Market Cap
$27.5M
Sector
Healthcare
AI Confidence
65%
TELA
TELA Bio, Inc.
BEARISH
Price
$0.63
Market Cap
$28.2M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
AYTU
--
TELA
--
Forward P/E
AYTU
15.88
TELA
-1.12
P/B Ratio
AYTU
1.15
TELA
4.44
P/S Ratio
AYTU
0.43
TELA
0.35
EV/EBITDA
AYTU
3.86
TELA
-1.07

Profitability

Gross Margin
AYTU
67.56%
TELA
68.17%
Operating Margin
AYTU
-10.83%
TELA
-31.86%
Profit Margin
AYTU
-20.52%
TELA
-48.37%
ROE
AYTU
-50.23%
TELA
-223.35%
ROA
AYTU
0.61%
TELA
-25.12%

Growth

Revenue Growth
AYTU
-16.2%
TELA
18.2%
Earnings Growth
AYTU
--
TELA
--

Financial Health

Debt/Equity
AYTU
1.23
TELA
9.13
Current Ratio
AYTU
1.23
TELA
4.21
Quick Ratio
AYTU
1.0
TELA
3.4

Dividends

Dividend Yield
AYTU
--
TELA
--
Payout Ratio
AYTU
0.0%
TELA
0.0%

AI Verdict

AYTU NEUTRAL

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating borderline financial health, and the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite unprofitability (ROE: -50.23%, Profit Margin: -20.52%) and declining revenue (YoY -16.20%), the stock has seen strong short-term price momentum (+61.7% 1Y) and a bullish analyst recommendation (strong_buy) with a high target price of $9.33. High gross margins (67.56%) and improving quarterly earnings surprises (avg +98.68% last 4 quarters) suggest operational progress, but weak cash visibility, leverage (Debt/Equity: 1.23), and inconsistent earnings history remain concerns. The stock trades at a forward P/E of 15.88, below sector average, potentially reflecting skepticism around sustainability.

Strengths
High gross margin (67.56%) indicates strong pricing power or low production costs
Recent earnings surprises significantly positive (avg +98.68% last 4 quarters)
Analyst consensus is strong_buy with a high target price ($9.33) implying 245% upside
Risks
Piotroski F-Score of 4/9 indicates weak financial health and poor profitability
Profitability remains negative (Profit Margin: -20.52%, ROE: -50.23%)
Revenue declining YoY (-16.20%) and limited financial transparency (missing cash/debt data)
TELA BEARISH

TELA exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a catastrophic ROE of -223.35%. While the company maintains a strong gross margin (68.17%) and modest revenue growth (18.2%), these are completely offset by extreme leverage (Debt/Equity of 9.13) and a consistent 25-quarter history of negative earnings. The stock's 5-year price collapse of 95.4% reflects a fundamental loss of investor confidence that is not countered by any meaningful insider buying or operational profitability.

Strengths
Strong Gross Margin of 68.17% indicating product value
Positive YoY Revenue Growth of 18.20%
High Current Ratio (4.21) providing short-term liquidity
Risks
Extreme financial leverage with a Debt/Equity ratio of 9.13
Severe lack of profitability with an ROE of -223.35%
Critical financial health as indicated by a Piotroski F-Score of 1/9

Compare Another Pair

AYTU vs TELA: Head-to-Head Comparison

This page compares Aytu BioPharma, Inc. (AYTU) and TELA Bio, Inc. (TELA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile